BKD Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Analyst Recommendation And ValuationAnalysts maintain buy ratings while applying a reduced valuation multiple versus peers, signaling confidence in the long-term upside given the current lower valuation.
Cost Reduction ProgramA large cost-reduction program is expected to support meaningful margin and earnings improvement if execution remains on track.
Diversified Business GrowthHealthy growth in businesses outside the weak U.S. market, including lab automation and spatial biology, supports diversified revenue prospects.
Bears Say
Guidance And Execution RiskCompany guidance implies a steep ramp in revenue and margins, increasing execution risk for achieving annual targets.
Margin ShortfallA reported quarterly gross margin shortfall raises questions about near-term profitability and puts pressure on investor confidence.
Revenue Seasonality And VisibilityUnusual revenue seasonality and irregular timing make it difficult for investors to observe steady progress and increase uncertainty around growth momentum.
Bruker News
BKD FAQ
What was Bruker Corporation’s price range in the past 12 months?
Currently, no data Available
What is Bruker Corporation’s market cap?
Currently, no data Available
When is Bruker Corporation’s upcoming earnings report date?
Bruker Corporation’s upcoming earnings report date is Aug 05, 2026 which is in 25 days.
How were Bruker Corporation’s earnings last quarter?
Bruker Corporation released its earnings results on May 06, 2026. The company reported $0.251 earnings per share for the quarter, beating the consensus estimate of $0.185 by $0.065.
Is Bruker Corporation overvalued?
According to Wall Street analysts Bruker Corporation’s price is currently Undervalued.
Does Bruker Corporation pay dividends?
Bruker Corporation does not currently pay dividends.
What is Bruker Corporation’s EPS estimate?
Bruker Corporation’s EPS estimate is 0.31.
How many shares outstanding does Bruker Corporation have?
Currently, no data Available
What happened to Bruker Corporation’s price movement after its last earnings report?
Bruker Corporation reported an EPS of $0.251 in its last earnings report, beating expectations of $0.185. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Bruker Corporation?
Currently, no hedge funds are holding shares in CH:BKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bruker Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.01 (― Downside)
$46.01 (― Downside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.49%
12-Months-Change
Fundamentals
Return on Equity
-0.51%
Trailing 12-Months
Asset Growth
3.33%
Trailing 12-Months
Company Description
Bruker Corporation
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
BKD Company Deck
BKD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously constructive picture: management beat Q1 expectations, highlighted multiple high-growth, AI-driven and idiosyncratic end-market opportunities (Semi Metrology, SciY, security detection, BEST superconductors), and is delivering cost savings above original targets while reconfirming full-year guidance. These positives are balanced against meaningful near-term organic revenue declines, China and academic funding weaknesses, margin and mix pressures, and EPS softening in Q1. On balance, the positive operational momentum (strong bookings, large multi-year orders, and expanded cost savings) and reconfirmed guidance slightly outweigh the current headwinds.View all CH:BKD earnings summariesBKD Stock 12 Month Forecast
Average Price Target
$46.01
Options Prices
Currently, No data available
---